VT-122 - Revision history

Lazy at 08:23, 18 January 2025

2025-01-18T08:23:26Z

← Older revision		Revision as of 01:23, 18 January 2025
Line 14:		Line 14:
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person		\|toxicity_explanation=VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person
	}}		\|overview=VT-122 is an investigational combination of repurposed drugs Propranolol and Etodolac, targeting cachexia in cancer patients, particularly in non-small cell lung cancer, hepatocellular carcinoma, and glioblastoma. Preliminary studies indicate improved overall survival rates when paired with low-dose temozolomide, but further research is needed to evaluate its safety and efficacy.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:36:21Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:36, 12 November 2024
Line 10:		Line 10:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.		\|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person		\|toxicity_explanation=VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person
	}}		}}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:29Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 12:		Line 12:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=3
			\|toxicity_explanation=VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person
	}}		}}

Lazy at 13:34, 24 March 2024

2024-03-24T13:34:19Z

← Older revision		Revision as of 06:34, 24 March 2024
Line 8:		Line 8:
	\|OS_with=In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122		\|OS_with=In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122
	\|PFS_with=Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies		\|PFS_with=Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies
	\|usefulness_rating=~~Investigational (specific rating not provided due to limited and preliminary data)~~		\|usefulness_rating=4
	\|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.		\|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=VT-122 (Propranolol and Etodolac combination) |FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer t..."

2024-03-24T13:32:09Z

Created page with "{{TreatmentInfo |drug_name=VT-122 (Propranolol and Etodolac combination) |FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer t..."

New page

{{TreatmentInfo
|drug_name=VT-122 (Propranolol and Etodolac combination)
|FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions)
|used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma
|clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer types)
|common_side_effects=Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies
|OS_without=In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone
|OS_with=In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122
|PFS_with=Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies
|usefulness_rating=Investigational (specific rating not provided due to limited and preliminary data)
|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.
|category=Repurposed Drugs
|links=
}}